Idiopathic pulmonary fibrosis: Tracking the true occurrence is challenging

European Respiratory Journal

Volumn 46, Issue 3, 2015, Pages 604-606

  Samet, Jonathan M ^a   Coultas, David ^b   Raghu, Ganesh ^c  

^a UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^b OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^c UNIVERSITY OF WASHINGTON   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AWARENESS; DISEASE COURSE; EDITORIAL; ELECTRONIC MEDICAL RECORD; ENVIRONMENTAL FACTOR; EPIDEMIOLOGICAL DATA; EUROPE; EVIDENCE BASED MEDICINE; FACTUAL DATABASE; FIBROSING ALVEOLITIS; GENETIC RISK; HEALTH CARE QUALITY; HUMAN; INCIDENCE; MEDICAL DOCUMENTATION; MEDICAL INFORMATION; MEDICAL LITERATURE; MORTALITY; NORTH AMERICA; PREVALENCE; PRIORITY JOURNAL; SMOKING; SYSTEMATIC REVIEW (TOPIC); CAUSE OF DEATH; FEMALE; HEALTH; IDIOPATHIC PULMONARY FIBROSIS; MALE;

CAUSE OF DEATH; FEMALE; GLOBAL HEALTH; HUMANS; IDIOPATHIC PULMONARY FIBROSIS; MALE;

EID: 84942741256     PISSN: 09031936     EISSN: 13993003     Source Type: Journal    
DOI: 10.1183/13993003.00958-2015     Document Type: Editorial

References (17)

1. US Department of Health and Human Services. The Health Consequences of Smoking - 50 Years of Progress: A Report of the Surgeon General. Atlanta, U.S. Department of Health and Human Services, Centers for Disease Control and Prevention, National Center for Chronic Disease Prevention and Health Promotion, Office on Smoking and Health, 2014.
2. Forman D, Bray F, Brewster DH, et al., eds. Cancer Incidence in Five Continents, Vol. X. Lyon, International Agency for Research on Cancer, 2014.
3. Kaunisto J, Salomaa ER, Hodgson U, et al. Idiopathic pulmonary fibrosis - a systematic review on methodology for the collection of epidemiological data. BMC Pulm Med 2013; 13: 53.
4. Taskar VS, Coultas DB. Is idiopathic pulmonary fibrosis an environmental disease? Proc Am Thorac Soc 2006; 3: 293-298.
5. Raghu G, Collard HR, Egan JJ, et al. An official ATS/ERS/JRS/ALAT statement: idiopathic pulmonary fibrosis: evidence-based guidelines for diagnosis and management. Am J Respir Crit Care Med 2011; 183: 788-824.
6. Hutchinson J, Fogarty A, Hubbard R, et al. Global incidence and mortality of idiopathic pulmonary fibrosis: a systematic review. Eur Respir J 2015; 46: 795-806.
7. Coultas DB, Zumwalt RE, Black WC, et al. The epidemiology of interstitial lung diseases. Am J Respir Crit Care Med 1994; 150: 967-972.
8. National Cancer Institute. Surveillance, Epidemiology, and End Results Program (SEER). 2015 http://seer.cancer.gov/statfacts/ Date last accessed: June 1, 2015.
9. Raghu G. Idiopathic pulmonary fibrosis: new evidence and an improved standard of care in 2012. Lancet 2012; 380: 699-701.
10. Raghu G, Chen SY, Yeh WS, et al. Idiopathic pulmonary fibrosis in US Medicare beneficiaries aged 65 years and older: incidence, prevalence, and survival, 2001-11. Lancet Respir Med 2014; 2: 566-572.
11. Collard HR, Chen SY, Yeh WS, et al. Health care utilization and costs in idiopathic pulmonary fibrosis in United States Medicare beneficiaries aged 65 years and older. Ann Am Thorac Soc 2015 [in press; doi: 10.1513 AnnalsATS.201412-553OC].
12. Wu N, Yu YF, Chuang CC, et al. Healthcare resource utilization among patients diagnosed with idiopathic pulmonary fibrosis in the United States. J Med Econ 2015; 18: 249-257.
13. Fernandez Perez ER, Daniels CE, Schroeder DR, et al. Incidence, prevalence, and clinical course of idiopathic pulmonary fibrosis: a population-based study. Chest 2010; 137: 129-137.
14. Navaratnam V, Fleming KM, West J, et al. The rising incidence of idiopathic pulmonary fibrosis in the U.K. Thorax 2011; 66: 462-467.
15. Ryerson CJ, Corte TJ, Collard HR, et al. A global registry for idiopathic pulmonary fibrosis: the time is now. Eur Respir J 2014; 44: 273-276.
16. Raghu G, Selman M. Nintedanib and pirfenidone. New antifibrotic treatments indicated for idiopathic pulmonary fibrosis offer hopes and raises questions. Am J Respir Crit Care Med 2015; 191: 252-254.
17. Karimi-Shah BA, Chowdhury BA. Forced vital capacity in idiopathic pulmonary fibrosis - FDA review of pirfenidone and nintedanib. N Engl J Med 2015; 372: 1189-1191.